In a bold and unexpected policy pivot, President Donald Trump signed an executive order on December 18, 2025, directing federal agencies to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This landmark decision acknowledges marijuana’s accepted medical uses, such as treating chronic pain, nausea, and anorexia, while recognizing its lower potential for abuse compared to substances like heroin. Building on a review process initiated under the Biden administration, the order accelerates rescheduling and introduces innovative measures, including a pilot program for Medicare coverage of hemp-derived CBD products.